Enteral diets: mode of therapeutic eVect
The clinical response to an enteral diet has been associated with a reduction in disease activity scores and in inflammatory markers. Decreased intestinal permeability, histological healing, and downregulation of mucosal proinflammatory cytokines 4 have also been reported. To date, the mechanisms underlying this therapeutic response remain unclear. Proposed theories include reduced antigenic load, provision of trophic amino acids, alterations in gut flora, and immune modulating eVects of fatty acids supplied by the feed. The quantity and type of fat in a liquid feed may be an important determinant of therapeutic response, a premise supported by reports of aberrant fatty acid profiles in CD 5 and better therapeutic outcome with lower fat and fat modified feeds.
Enteral diets: nutritional role
Undernutrition, weight loss, and poor nutritional status have been reported at all stages of CD-at diagnosis, during active disease, and in remission. Undernutrition further complicates CD; moreover, villous atrophy 6 and gastrointestinal dysfunction associated with severe undernutrition may have direct negative implications for mucosal healing. In children and adolescents with CD, the eVects of undernutrition combined with corticosteroid therapy have a severe negative impact on linear growth. An estimated 70% of patients with early onset Crohn's fail to meet their expected height by adulthood. These are strong grounds to favour enteral nutrition as primary therapy in paediatric CD. Furthermore, use of supplemental enteral nutrition after diet induced remission has been associated with improved linear growth and prolonged remission. Careful nutritional monitoring and appropriate intervention are clearly required in both children and adults and at all stages of disease.
Enteral diet: a Crohn's disease specific formula
Specific constituents of an enteral feed may aid mucosal repair and protective mechanisms in CD. There has long been an interest in the role of glutamine, although a recent controlled trial could find no benefit associated with a glutamine enriched polymeric formula in the treatment of CD. 7 In another recent study, butyrate was reported to downregulate inflammatory cytokine expression via inhibition of nuclear factor B in CD. 8 In the future, these and other elements, including pre-and probiotics, short chain fatty acids, and growth factors may have a place in a CD specific formula. In the face of increasingly advanced immune modulatory therapies, enteral diets may seem rather mundane. Nevertheless, these diets may well oVer an ideal and safe mode of delivery of immune modulatory nutrients/substrates directly to the gastrointestinal mucosa.
